BioXcel Therapeutics, Inc. (BTAI) › Operating IncomeBioXcel Therapeutics, Inc. (BTAI) — Operating IncomeAnnual figures by period end, from SEC filings.2017-12-31: -$4.54M2018-12-31: -$19.96M2019-12-31: -$33.60M2020-12-31: -$82.30M2021-12-31: -$106.94M2022-12-31: -$159.65M2023-12-31: -$171.78M2024-12-31: -$67.25M2025-12-31: -$50.46M-$50.46M2017-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31-$50.46M—2026-03-27From 2025-01-012024-12-31-$67.25M—2026-03-27From 2024-01-012023-12-31-$171.78M—2025-03-28From 2023-01-012022-12-31-$159.65M—2024-03-22From 2022-01-012021-12-31-$106.94M—2023-03-16From 2021-01-012020-12-31-$82.30M—2022-03-11From 2020-01-012019-12-31-$33.60M—2021-03-12From 2019-01-012018-12-31-$19.96M—2020-03-09From 2018-01-012017-12-31-$4.54M—2019-03-12From 2017-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)